Jean Claude Bystryn

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Treatment options in pemphigus
    J C Bystryn
    The Ronald O Perelman Department of Dermatology, The New York University School of Medicine, New York, NY, USA
    G Ital Dermatol Venereol 144:351-61. 2009
  2. ncbi IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris
    Jean Claude Bystryn
    The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
    Autoimmunity 39:601-7. 2006
  3. ncbi Pemphigus
    Jean Claude Bystryn
    The Ronald O Perelman Department of Dermatology, New York University School of Medicine, 560 1st Avenue, New York, NY 10016, USA
    Lancet 366:61-73. 2005
  4. ncbi Emerging melanoma vaccines
    Jean Claude Bystryn
    New York University School of Medicine, The Ronald O Perelman Department of Dermatology, NYU Cancer Institute, New York, NY, USA
    Expert Opin Emerg Drugs 10:393-402. 2005
  5. ncbi Melanoma vaccines: what we know so far
    Jean Claude Bystryn
    The Ronald O Perelman Department of Dermatology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York, USA
    Oncology (Williston Park) 19:97-108; discussion 108, 111-2, 115. 2005
  6. doi Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies
    Annette Czernik
    Department of Dermatology, New York University School of Medicine, 550 First Ave, Tisch Hospital, H313, New York, NY 10016, USA
    Arch Dermatol 144:658-61. 2008
  7. ncbi Vaccines for melanoma
    Jean Claude Bystryn
    Ronald O Perelman Department of Dermatology and Melanoma Program, Melanoma Immunotherapy Clinic, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 35 East 35th Street, Suite 208, New York, NY 10016, USA
    Dermatol Clin 20:717-25. 2002
  8. ncbi Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice
    Dean Johnston
    Hunter College School of Health Sciences, New York, NY, USA
    Cancer Immunol Immunother 55:412-9. 2006
  9. ncbi Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma
    Sandra R Reynolds
    Department of Dermatology, New York University School of Medicine, Kaplan Comprehensive Cancer Center, New York, New York 10016, USA
    Clin Cancer Res 9:657-62. 2003
  10. ncbi Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma
    Sandra R Reynolds
    Department of Dermatology, Kaplan Comprehensive Cancer Center New York University School of Medicine, New York, New York 10016, USA
    Clin Cancer Res 9:1497-502. 2003

Research Grants

Collaborators

Detail Information

Publications40

  1. ncbi Treatment options in pemphigus
    J C Bystryn
    The Ronald O Perelman Department of Dermatology, The New York University School of Medicine, New York, NY, USA
    G Ital Dermatol Venereol 144:351-61. 2009
    ....
  2. ncbi IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris
    Jean Claude Bystryn
    The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
    Autoimmunity 39:601-7. 2006
    ..The mechanism by which it does so is not known. The following study was conducted to confirm the effectiveness of IVIg for the acute control of active PV and to elucidate the mechanism by which it does...
  3. ncbi Pemphigus
    Jean Claude Bystryn
    The Ronald O Perelman Department of Dermatology, New York University School of Medicine, 560 1st Avenue, New York, NY 10016, USA
    Lancet 366:61-73. 2005
    ..Immunosupressants, anti-inflammatory drugs, and antibiotics are used as adjuvants, but apart from IVIg, these therapy options are non-specific and more research is needed to develop treatments with improved side-effect profiles...
  4. ncbi Emerging melanoma vaccines
    Jean Claude Bystryn
    New York University School of Medicine, The Ronald O Perelman Department of Dermatology, NYU Cancer Institute, New York, NY, USA
    Expert Opin Emerg Drugs 10:393-402. 2005
    ....
  5. ncbi Melanoma vaccines: what we know so far
    Jean Claude Bystryn
    The Ronald O Perelman Department of Dermatology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York, USA
    Oncology (Williston Park) 19:97-108; discussion 108, 111-2, 115. 2005
    ....
  6. doi Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies
    Annette Czernik
    Department of Dermatology, New York University School of Medicine, 550 First Ave, Tisch Hospital, H313, New York, NY 10016, USA
    Arch Dermatol 144:658-61. 2008
    ..We propose that the addition of immunosuppressive agents to the IVIg regimen may increase the ability of IVIg to lower the level of pathogenic antibodies...
  7. ncbi Vaccines for melanoma
    Jean Claude Bystryn
    Ronald O Perelman Department of Dermatology and Melanoma Program, Melanoma Immunotherapy Clinic, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 35 East 35th Street, Suite 208, New York, NY 10016, USA
    Dermatol Clin 20:717-25. 2002
    ..To establish the true effectiveness of vaccines in the treatment of malignant melanoma, several large, prospectively randomized phase III studies are currently being conducted...
  8. ncbi Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice
    Dean Johnston
    Hunter College School of Health Sciences, New York, NY, USA
    Cancer Immunol Immunother 55:412-9. 2006
    ..This may provide a simple, safe, and effective way to enhance the immunogenicity of vaccines that consist of pure protein antigens...
  9. ncbi Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma
    Sandra R Reynolds
    Department of Dermatology, New York University School of Medicine, Kaplan Comprehensive Cancer Center, New York, New York 10016, USA
    Clin Cancer Res 9:657-62. 2003
    ..The following study was conducted to examine whether these responses are associated with improved clinical outcome in melanoma vaccine-treated patients...
  10. ncbi Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma
    Sandra R Reynolds
    Department of Dermatology, Kaplan Comprehensive Cancer Center New York University School of Medicine, New York, New York 10016, USA
    Clin Cancer Res 9:1497-502. 2003
    ..Melanoma cells can be found in the circulation of patients with melanoma. The following study was conducted to examine whether changes in their presence could provide an early marker of response to therapy...
  11. ncbi Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?
    Sandra R Reynolds
    Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
    Int J Cancer 119:157-61. 2006
    ..Measurement of CYT-MAA serum level during therapy could provide an intermediate marker of response in these patients...
  12. ncbi Treatment of pemphigus with intravenous immunoglobulin
    Jean Claude Bystryn
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York 10016, USA
    J Am Acad Dermatol 47:358-63. 2002
    ..This study was conducted to re-examine the effectiveness of IVIg for the immediate control of active disease and to study the mechanisms of its action...
  13. ncbi Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice
    Dean Johnston
    Hunter College School of Health Sciences, 425 East 25th Street, New York, NY 10010, USA
    Cancer Immunol Immunother 54:345-50. 2005
    ..Heterogeneity may hamper interpretation of vaccine immunogenicity and relevant tumor antigens in humans...
  14. ncbi TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
    Dean Johnston
    Hunter College School of Health Sciences, New York, NY, USA
    Cancer Immunol Immunother 56:1133-41. 2007
    ..The lack of toxicity also indicates that this combination may by safe, effective method to boost immune response to cancer vaccines...
  15. doi Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus
    Annette Czernik
    The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA
    J Am Acad Dermatol 58:796-801. 2008
    ..The following study was conducted to confirm observations made in a limited number of patients that suggest intravenous immunoglobulin (IVIg) may be able to selectively lower serum levels of only abnormal autoantibodies...
  16. ncbi Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update
    Annette Czernik
    Department of Dermatology, University of California, Irvine, CA 92697 2400, USA
    Autoimmunity 45:111-8. 2012
    ....
  17. doi Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies
    Margarita Lolis
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
    J Am Acad Dermatol 64:484-9. 2011
    ..Intravenous immunoglobulin (IVIg)--a relatively new approach to treat pemphigus--lowers serum levels of pemphigus antibodies; however, the optimal way to use this agent is unknown...
  18. doi Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid
    Siavash Toosi
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Med Hypotheses 74:727-8. 2010
    ..The information obtained could also lead to the development of novel therapeutic strategies for this and other autoimmune blistering diseases...
  19. doi Jean-Claude Bystryn 1938-2010. An obituary
    Sergei A Grando
    Department of Dermatology, University, California, Irvine, NJ, USA
    Exp Dermatol 20:293-6. 2011
    ..Dr. Bystryn was an innovative physician-scientist whose scientific contributions will be long recalled and admired both by patients and colleagues...
  20. ncbi A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis
    Jean Claude Bystryn
    Department of Dermatology, New York University School of Medicine, New York, New York, USA
    J Am Acad Dermatol 54:513-6. 2006
  21. ncbi Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris
    Michelle G Green
    Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
    Arch Dermatol 144:1621-4. 2008
    ..This study was conducted to study the effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antibodies against desmoglein 1 and desmoglein 3 in patients with pemphigus vulgaris...
  22. ncbi Improved identification of potentially dangerous pigmented skin lesions by computerized image analysis
    Maria Jasmin Jamora
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
    Arch Dermatol 139:195-8. 2003
    ....
  23. ncbi Why is the mortality of bullous pemphigoid greater in Europe than in the US?
    Jean Claude Bystryn
    Ronald O Perelman Department of Dermatology, NYU School of Medicine, New York, New York, USA
    J Invest Dermatol 124:xx-xxi. 2005
  24. ncbi Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris
    Maria Jasmin J Jamora
    Department of Dermatology, New York University School of Medicine, New York, New York, USA
    J Am Acad Dermatol 48:976-7. 2003
  25. pmc Reliability and convergent validity of two outcome instruments for pemphigus
    Misha Rosenbach
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19119, USA
    J Invest Dermatol 129:2404-10. 2009
    ..Subset analysis suggests that for this population of mild-to-moderate disease activity, the PDAI captures more variability in cutaneous disease than the ABSIS...
  26. pmc Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod
    Caroline Othoro
    Department of Medical Parasitology, New York University Cancer Institute, School of Medicine, New York University, New York, New York 10010, USA
    Infect Immun 77:739-48. 2009
    ....
  27. ncbi Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic pemphigus foliaceus (Fogo Selvagem)
    Paulo Rowilson Cunha
    Department of Dermatology, Faculty of Medicine de JundiaĆ­, Sao Paulo, Brazil
    Int J Dermatol 45:914-8. 2006
    ..Scientific literature certifies that both ELISA and IIF bear high sensitivity in spite of the fact that a direct comparison between the ELISA and IIF tests has never been performed...
  28. ncbi IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it
    Jean Claude Bystryn
    Ronald O Perelman Department of Dermatology New York University School of Medicine New York, NY
    J Invest Dermatol 125:1093-8. 2005
  29. ncbi Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine
    Dean Johnston
    Hunter College School of Health Sciences, 425 East 25th Street, New York NY 10010, USA
    Vaccine 24:1958-65. 2006
    ....
  30. ncbi Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy
    Paulo Rowilson Cunha
    Department of Dermatology, Faculdade de Medicina de Jundiai, Sao Paulo, Brazil
    Int J Dermatol 43:682-4. 2004
  31. ncbi Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus
    Jean Claude Bystryn
    Arch Dermatol 138:1252-3. 2002
  32. doi Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid
    Jean Claude Bystryn
    Arch Dermatol 144:946. 2008
  33. doi Kinetics of response to conventional treatment in patients with pemphigus vulgaris
    Annette Czernik
    Arch Dermatol 144:682-3. 2008
  34. pmc Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
    Dedee F Murrell
    Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
    J Am Acad Dermatol 58:1043-6. 2008
    ..These should assist in development of consistent reporting of outcomes in future studies...
  35. ncbi Frequency of shifts over time in the profile of antidesmoglein antibodies in pemphigus vulgaris
    Daniel Weitz
    Arch Dermatol 143:1073-4. 2007
  36. ncbi A confusing message will not improve the detection of melanoma
    Jean Claude Bystryn
    Arch Dermatol 143:806; author reply 806-7. 2007
  37. ncbi Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancer
    Jean Claude Bystryn
    Arch Dermatol 143:804; author reply 804-5. 2007
  38. ncbi Cutaneous pemphigus vulgaris: what causes it?
    Jean Claude Bystryn
    J Am Acad Dermatol 55:175-6; author reply 176-7. 2006
  39. ncbi Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists?
    Jean Claude Bystryn
    Arch Dermatol 138:1378. 2002
  40. ncbi Oral and topical corticosteroids in bullous pemphigoid
    Jean Claude Bystryn
    N Engl J Med 347:143-5; author reply 143-5. 2002

Research Grants8

  1. POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2001
    ..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
  2. Polypeptide Vaccine In IL-2 Liposomes For Prostate Ca
    Jean Claude Bystryn; Fiscal Year: 2002
    ..Successful completion of this work may provide a new treatment for prostate cancer that has minimal toxicity, that improves quality of life, and that has the ultimate potential to prevent this cancer. ..
  3. POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2002
    ..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
  4. POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2004
    ..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
  5. PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONS
    Jean Claude Bystryn; Fiscal Year: 2005
    ..We expect it will attract 100-150 scientists and clinicians dedicated to investigate and treating pemphigus. ..
  6. PHASE II RANDOMIZED TRIAL OF IVIG WITH OR WITHOUT CYCLOPHOSPHAMIDE IN PEMPHIGUS
    Jean Claude Bystryn; Fiscal Year: 2007
    ..By improving the effectiveness of IVIg, it would also reduce the cost of this very expensive treatment and minimize its toxicity. [unreadable] [unreadable] [unreadable]..
  7. SERUM CYT-MAA AS AN EARLY MARKER OF RESPONSE TO THERAPY IN RESECTED MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..